{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-23-001254","form_type":"8-K","ticker":"MIRM","cik":"0001759425","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.135744+00:00","generated_at":"2026-06-12T08:56:46.483436+00:00","sec_items":["2.02","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Mirum reports Q2 revenue $37.5M, LIVMARLI sales $32.5M; acquires CHENODAL/CHOLBAM for $210M","bullets":["Q2 total revenue $37.5M (incl $5M license); LIVMARLI net sales $32.5M, up 86% YoY.","Acquiring CHENODAL and CHOLBAM from Travere for $210M upfront + up to $235M milestones.","Entered $210M private placement to fund acquisition; closed $316.3M convertible notes at 4% due 2029.","Pipeline readouts H2 2023: EMBARK (biliary atresia), volixibat PSC/PBC, CHENODAL RESTORE.","Cash $330M as of June 30; repurchased 9.75% royalty obligation."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-23-001254","json":"https://secwatch.observer/filing/0001157523-23-001254.json","markdown":"https://secwatch.observer/filing/0001157523-23-001254.md","text":"https://secwatch.observer/filing/0001157523-23-001254.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759425/000115752323001254/0001157523-23-001254-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759425/000115752323001254/a53507837.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T08:56:46.483436+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"897f18f381c2096c1a0c94feea5e54236cb8055b","claim":"Mirum Pharmaceuticals, Inc. reported the quarter ended June 30, 2023 results: revenue $37.5 million.","evidence_excerpt":"Total revenue for the quarter ended June 30, 2023 was $37.5 million, including $5.0 million of license revenue, compared to $17.5 million in total revenue for the quarter ended June 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759425/000115752323001254/0001157523-23-001254-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"$37.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}